Dx & Vx Co., Ltd.
Financials
Valuation Metrics
Dx & Vx Co., Ltd.'s Market Cap is ₩1833B. At end of 2025 it was ₩3091B. Ranked #847 of 2,405 in KR market (top 35%), #386 of 1,627 on KOSDAQ (top 24%), #94 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 183.28B KRW | KR#847/2,405 Sec#94/231 |
| Revenue | 26.22B KRW | KR#2,072/2,405 Sec#146/231 |
| Net Income | -26.84B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 107.49B KRW | KR#1,722/2,405 Sec#135/231 |
| Net Assets | 83.89B KRW | KR#1,552/2,405 Sec#124/231 |
| Employees | 121 | KR#1,493/2,405 Sec#119/231 |
| Value | ||
| P/B | 2.18x | KR#2,019/2,405 Sec#155/231 |
| P/S | 6.99x | KR#2,227/2,405 Sec#157/231 |
| FCF Yield | -10.83% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -32.00% | KR#2,189/2,405 Sec#181/231 |
| ROA | -24.97% | KR#2,267/2,405 Sec#189/231 |
| Op. Margin | -80.17% | KR#2,271/2,405 Sec#168/231 |
| Revenue Growth | -9.44% | KR#1,906/2,405 Sec#177/231 |
| Financial Health | ||
| Debt Ratio | 28.14% | KR#540/2,405 Sec#60/231 |
| Total Debt | 10.72B KRW | KR#1,591/2,405 Sec#144/231 |
| FCF | -19.85B KRW | KR#1,882/2,405 Sec#179/231 |
| Cash | 28.30B KRW | KR#1,040/2,405 Sec#73/231 |
| Current Ratio | 4.14x | KR#357/2,405 Sec#56/231 |
| Performance | ||
| 1Y Return | -5.53% | KR#674/2,405 Sec#36/231 |
| 1M Return | -19.04% | KR#1,815/2,405 Sec#176/231 |
| From 52W High | -65.26% | KR#1,899/2,405 Sec#162/231 |
| 1Y MDD | -64.38% | KR#1,687/2,405 Sec#139/231 |
| Trading | ||
| Volume | 25,225 shares | KR#1,374/2,405 Sec#131/231 |
| Trading Value | 46.4M KRW | KR#1,765/2,405 Sec#188/231 |
| Foreign Own. | 4.91% | KR#870/2,405 Sec#77/231 |
| Per Share | ||
| EPS | -273 KRW | KR—/2,405 Sec—/231 |
| BPS | 852 KRW | KR#2,321/2,405 Sec#216/231 |
Company Info
DXVX, established in 2001, is a bio-healthcare specialized company that listed on KOSDAQ in 2015. It has expanded its business through the acquisition of Korea Biopharm in 2022, and the establishment of a Chinese subsidiary and acquisition of Evixgen in 2023. The medical diagnostics division focuses on NGS and DNA chip-based genomic diagnostics, along with the development and manufacturing of PCR molecular diagnostic and rapid immune diagnostic kits. The new drug development division aims to reduce financial risk by developing diverse pipelines and implementing stage-by-stage license transfers. DXVX is headquartered in Geumcheon-gu, Seoul.